Trajectories of medication for opioid use disorder and their impact on HIV testing among people who inject drugs in India: A longitudinal assessment of clinic-based data

被引:0
作者
Mcfall, Allison M. [1 ]
Ganapathi, Lakshmi [2 ]
Gunaratne, Mihili P. [1 ]
Srikrishnan, Aylur K. [3 ]
Vasudevan, Conjeevaram K. [3 ]
Anand, Santhanam [4 ]
Solomon, Sunil S. [5 ]
Mehta, Shruti H. [1 ]
Lucas, Gregory M. [5 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA
[2] Massachusetts Gen Hosp, Div Pediat Global Hlth, Boston, MA USA
[3] YR Gaitonde Ctr AIDS Res & Educ, Chennai, India
[4] A Square Consultancy, Chennai, India
[5] Johns Hopkins Univ, Infect Dis Dept, Sch Med, Baltimore, MD USA
关键词
India; HIV; HIV testing; medication for opioid use disorder; OST; People who inject drugs; trajectory; SUBSTITUTION TREATMENT; BUPRENORPHINE; THERAPY;
D O I
10.1111/add.16713
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
AimsThe aim of this study was to identify longitudinal trajectories of medication for opioid use disorder (MOUD) use throughout 1 year following MOUD initiation and to examine the association of trajectory membership with HIV testing among people who inject drugs in India.Design, setting and participantsThe study comprised group-based trajectory modeling using longitudinal clinic-based MOUD use data, set in seven Indian cities with integrated care centers (ICC) delivering MOUD, predominantly buprenorphine, in 2018-2019. A total of 1562 people who inject drugs who initiated MOUD for the first time at an ICC between 1 January 2018 and 31 December 2018 were included in this study. Median age was 26 years, 98% were male and 22% were living with HIV.MeasurementsDaily directly observed MOUD visits were biometrically verified and entered into an electronic database. A dichotomous variable for MOUD use each day throughout 1 year following initiation was created for the trajectory models. Client socio-demographics, HIV status and testing at the ICC and dose were extracted from the clinical database.FindingsWe found five MOUD trajectory groups: (1) early dropout (41%), (2) late dropout (18%), (3) delayed dropout (10%), (4) intermittent use (12%) and (5) persistent use (19%). Differences between the dropout groups were characterized by the rate of decline in MOUD use over time. The late dropout group had an 18% higher rate of HIV testing [adjusted rate ratio (aRR) = 1.18, 95% confidence interval (CI) = 1.10-1.27] and those with persistent MOUD use had a 91% higher rate of testing (aRR = 1.91, 95% CI = 1.77-2.05) compared with the early dropout group.ConclusionsNearly 70% of clients initiating medication for opioid use disorder (MOUD) at integrated care centers (ICCs) in India stop MOUD use within 1 year, with trajectories characterized by the rate of decline in engagement. Clients with better MOUD adherence appear to return more frequently for HIV testing at the ICCs, underscoring the value of integrated care models.
引用
收藏
页码:745 / 755
页数:11
相关论文
共 33 条
[1]  
Ambekar A., 2019, MAGNITUDE SUBSTANCE
[2]   Challenges in the scale-up of opioid substitution treatment in India [J].
Ambekar, Atul ;
Murthy, Pratima ;
Basu, Debasish ;
Rao, G. Prasad ;
Mohan, Ashwin .
INDIAN JOURNAL OF PSYCHIATRY, 2017, 59 (01) :6-9
[3]  
Dhawan A., 2010, OPIOID SUBSTITUTIONB
[4]   Buprenorphine treatment receipt characteristics and retention among people who inject drugs at Integrated Care Centers in India [J].
Ganapathi, Lakshmi ;
McFall, Allison M. ;
Greco, Kimberly F. ;
Srikrishnan, Aylur K. ;
Kumar, Muniratnam Suresh ;
Mayer, Kenneth H. ;
'Cleirigh, Conall ;
Mehta, Shruti H. ;
Lucas, Gregory M. ;
Solomon, Sunil S. .
DRUG AND ALCOHOL DEPENDENCE, 2023, 246
[5]   Young and invisible: a qualitative study of service engagement by people who inject drugs in India [J].
Ganapathi, Lakshmi ;
Srikrishnan, Aylur K. ;
Martinez, Clarissa ;
Lucas, Gregory M. ;
Mehta, Shruti H. ;
Verma, Vinita ;
McFall, Allison M. ;
Mayer, Kenneth H. ;
Hassan, Areej ;
Rajan, Shobini ;
O'Cleirigh, Conall ;
Harris, Sion Kim ;
Solomon, Sunil S. .
BMJ OPEN, 2021, 11 (09)
[6]   Oral substitution treatment of injecting opioid users for prevention of HIV infection [J].
Gowing, Linda ;
Farrell, Michael F. ;
Bornemann, Reinhard ;
Sullivan, Lynn E. ;
Ali, Robert .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (08)
[7]  
Gowing LR, 2013, B WORLD HEALTH ORGAN, V91, P148
[8]   Global opioid agonist treatment: a review of clinical practices by country [J].
Jin, Harry ;
Marshall, Brandon D. L. ;
Degenhardt, Louisa ;
Strang, John ;
Hickman, Matt ;
Fiellin, David A. ;
Ali, Robert ;
Bruneau, Julie ;
Larney, Sarah .
ADDICTION, 2020, 115 (12) :2243-2254
[9]  
Kim J., 2021, CLIN INFECT DIS, V73, P1951, DOI DOI 10.1093/CID/CIAB578
[10]  
Kleber Herbert D, 2007, Dialogues Clin Neurosci, V9, P455